Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí hóa học đề tài : Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study | Andreis et al. Health and Quality of Life Outcomes 2010 8 40 http content 8 1 40 I HEALTH AND QUALITY OF LIFE OUTCOMES RESEARCH Open Access Quality of life in colon cancer patients with skin side effects preliminary results from a monocentric cross sectional study Federica Andreis 1 Anna Rizzi1 Paola Mosconi2 Claudia Braun2 Luigina Rota1 Fausto Meriggi1 Maria Mazzocchi1 and Alberto Zaniboni 1 Abstract Background Epidermal growth factor receptor inhibitors are widely prescribed anticancer drugs. Patients treated commonly develop dermatologic adverse drugs reactions but rarely they are involved in systematic evaluation of their quality of life. This monocentric cross sectional study is carried out to assess quality of life in colon cancer patients experienced skin side effects due to anti epidermal growth factor receptor inhibitors therapy. Methods Consecutive patients with skin side effects to therapy treated at Fondazione Poliambulanza were enrolled in this study. Quality of life was evaluated with the Italian validated version of Skindex-29 questionnaire exploring three dimensions symptoms emotional and physical functioning. Skindex-29 was administered one time between the eighth and the twelfth week of the treatment. Results Forty-five consecutive patients mainly with metastatic colon cancer 29 female 16 male with an average age of years ranging from 34-78 were included in the study and analyzed. Patients showed a great impact of skin side effects on symptoms mean 43 followed by emotional mean 30 and functioning mean 26 scales. In general women the 55-65 age class and patients with partial remission reported the worst quality of life. Conclusions Epidermal growth factor receptor inhibitors skin side effects have an important impact on quality of life in advanced colon cancer patients symptoms scale is the most effect respect to emotional and functioning scales. Background Epidermal growth factor receptor EGFR inhibitors as cetuximab or .
